Invention Grant
US08093302B2 Substituted tetralins as selective estrogen receptor-β agonists
失效
取代的四氢化萘作为选择性雌激素受体 - 激动剂
- Patent Title: Substituted tetralins as selective estrogen receptor-β agonists
- Patent Title (中): 取代的四氢化萘作为选择性雌激素受体 - 激动剂
-
Application No.: US11814806Application Date: 2006-02-10
-
Publication No.: US08093302B2Publication Date: 2012-01-10
- Inventor: Elizabeth Marie Thomas , Bryan Hurst Norman , Julian Stanley Kroin
- Applicant: Elizabeth Marie Thomas , Bryan Hurst Norman , Julian Stanley Kroin
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent John C. Demeter
- International Application: PCT/US2006/004540 WO 20060210
- International Announcement: WO2006/088716 WO 20060824
- Main IPC: A61K31/045
- IPC: A61K31/045 ; A61K31/135 ; A61K31/05 ; A61K31/075 ; C07C211/00 ; C07C43/02 ; C07C43/20 ; C07C35/42 ; C07C39/12
Abstract:
The present invention relates to novel tetralin ER-β agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-β mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis.
Public/Granted literature
- US20100249075A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS Public/Granted day:2010-09-30
Information query
